@article{oai:nagasaki-u.repo.nii.ac.jp:00026301,
 author = {Nemoto, Masahiro and Zaizen, Yoshiaki and Kataoka, Kensuke and Kuroda, Kishio and Tabata, Kazuhiro and Bychkov, Andrey and Sumikawa, Hiromitsu and Johkoh, Takeshi and Aoshima, Masahiro and Kondoh, Yasuhiro and Fukuoka, Junya},
 issue = {1},
 journal = {PLOS ONE},
 month = {Jan},
 note = {Background Histopathologic factors predictive of nintedanib efficacy in idiopathic pulmonary fibrosis have not been studied. We aimed to describe the characteristics, focusing on histopathology, of idiopathic pulmonary fibrosis patients who did and did not respond to nintedanib. Methods This study retrospectively examined the clinicoradiopathologic features of 40 consecutive patients with surgical lung biopsy-confirmed idiopathic pulmonary fibrosis treated with nintedanib. Additionally, we compared the histopathologic scoring of 21 microscopic features between patients with functional or radiological progression and those with non-progression during 12 months of treatment. Results The histopathologic evaluation showed edematous changes in the interlobular septum as the only histologic finding observed more frequently in patients with both functional and radiological progression than in those without (58% vs. 14%, P = 0.007 and 50% vs. 0%, P = 0.003, respectively). Regarding per-year change, patients with edematous changes in the interlobular septum showed greater progression in median changes in spared area (-12%, interquartile range: [-25%-5%], vs. -3% [-7%-0%], P = 0.004) and reticular shadow (7% [3%-13%], vs. 0% [0%-5%], P = 0.041) on computed tomography. Functional and radiological progression-free survival were shorter in patients with edematous changes in the interlobular septum than in those without 
(6.6 months, 95% confidence interval: [5.9-25.3], vs. event <50%, [12.1-Not available], P = 0.0009, and 6.1 months, [5.2-6.6] vs. 14.5 months [7.8-not available], P<0.0001). Conclusions Edematous changes in the interlobular septum may indicate poor nintedanib efficacy in idiopathic pulmonary fibrosis. Further studies are needed to validate these findings and address the mechanism behind ECIS., PLOS ONE, 16, art.no.e0245147; 2021},
 title = {Histologic factors associated with nintedanib efficacy in patients with idiopathic pulmonary fibrosis},
 volume = {16},
 year = {2021}
}